These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 37491748)

  • 1. Favourable outcomes in RR-TB patients using BPaL and other WHO-recommended second-line anti-TB drugs.
    Rikhotso MC; Ledwaba SE; Ngandu JK; Mavumengwana V; Kinnear CJ; Warren R; Potgieter N; Traoré AN
    Int J Tuberc Lung Dis; 2023 Aug; 27(8):599-605. PubMed ID: 37491748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines.
    Gomez GB; Siapka M; Conradie F; Ndjeka N; Garfin AMC; Lomtadze N; Avaliani Z; Kiria N; Malhotra S; Cook-Scalise S; Juneja S; Everitt D; Spigelman M; Vassall A
    BMJ Open; 2021 Dec; 11(12):e051521. PubMed ID: 34862287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe.
    Günther G; Guglielmetti L; Kherabi Y; Duarte R; Lange C;
    Clin Microbiol Infect; 2024 Sep; 30(9):1197.e1-1197.e4. PubMed ID: 38490355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysis.
    Hasan T; Medcalf E; Nyang'wa BT; Egizi E; Berry C; Dodd M; Foraida S; Gegia M; Li M; Mirzayev F; Morgan H; Motta I; Nguyen L; Schumacher S; Schlub T; Fox G
    Clin Infect Dis; 2024 Mar; 78(3):730-741. PubMed ID: 37874021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implementation of Bedaquiline, Pretomanid, and Linezolid in the United States: Experience Using a Novel All-Oral Treatment Regimen for Treatment of Rifampin-Resistant or Rifampin-Intolerant Tuberculosis Disease.
    Haley CA; Schechter MC; Ashkin D; Peloquin CA; Peter Cegielski J; Andrino BB; Burgos M; Caloia LA; Chen L; Colon-Semidey A; DeSilva MB; Dhanireddy S; Dorman SE; Dworkin FF; Hammond-Epstein H; Easton AV; Gaensbauer JT; Ghassemieh B; Gomez ME; Horne D; Jasuja S; Jones BA; Kaplan LJ; Khan AE; Kracen E; Labuda S; Landers KM; Lardizabal AA; Lasley MT; Letzer DM; Lopes VK; Lubelchek RJ; Patricia Macias C; Mihalyov A; Misch EA; Murray JA; Narita M; Nilsen DM; Ninneman MJ; Ogawa L; Oladele A; Overman M; Ray SM; Ritger KA; Rowlinson MC; Sabuwala N; Schiller TM; Schwartz LE; Spitters C; Thomson DB; Tresgallo RR; Valois P; Goswami ND;
    Clin Infect Dis; 2023 Oct; 77(7):1053-1062. PubMed ID: 37249079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis.
    James LP; Klaassen F; Sweeney S; Furin J; Franke MF; Yaesoubi R; Chesov D; Ciobanu N; Codreanu A; Crudu V; Cohen T; Menzies NA
    PLoS Med; 2024 May; 21(5):e1004401. PubMed ID: 38701084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts.
    Oelofse S; Esmail A; Diacon AH; Conradie F; Olayanju O; Ngubane N; Howell P; Everitt D; Crook AM; Mendel CM; Wills GH; Olugbosi M; Del Parigi A; Sun E; Calatroni A; Spigelman M; Dheda K
    Int J Tuberc Lung Dis; 2021 Jun; 25(6):453-460. PubMed ID: 34049607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
    Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
    Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meropenem-vaborbactam restoration of first-line drug efficacy and comparison of meropenem-vaborbactam-moxifloxacin versus BPaL MDR-TB regimen.
    Singh S; Gumbo T; Alffenaar JW; Boorgula GD; Shankar P; Thomas TA; Dheda K; Malinga L; Raj P; Aryal S; Srivastava S
    Int J Antimicrob Agents; 2023 Dec; 62(6):106968. PubMed ID: 37726063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of MDR, Pre-XDR, XDR, and Rifampicin-Resistant Tuberculosis or in Case of Intolerance to at Least Rifampicin in Austria, Germany, and Switzerland.
    Otto-Knapp R; Bauer T; Brinkmann F; Feiterna-Sperling C; Friesen I; Geerdes-Fenge H; Hartmann P; Häcker B; Heyckendorf J; Kuhns M; Lange C; Maurer FP; Nienhaus A; Priwitzer M; Richter E; Salzer HJF; Schoch OD; Schönfeld N; Schaberg T
    Respiration; 2024; 103(9):593-600. PubMed ID: 38810608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel 6-Month Treatment for Drug-Resistant Tuberculosis, United States.
    Haley CA; Macias P; Jasuja S; Jones BA; Rowlinson MC; Jaimon R; Onderko P; Darnall E; Gomez ME; Peloquin C; Ashkin D; Goswami ND
    Emerg Infect Dis; 2021 Jan; 27(1):332-4. PubMed ID: 33227229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sterile tuberculous granuloma in a patient with XDR-TB treated with bedaquiline, pretomanid and linezolid.
    Howell P; Upton C; Mvuna N; Olugbosi M
    BMJ Case Rep; 2021 Dec; 14(12):. PubMed ID: 34876446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Budgetary impact of using BPaL for treating extensively drug-resistant tuberculosis.
    Mulder C; Rupert S; Setiawan E; Mambetova E; Edo P; Sugiharto J; Useni S; Malhotra S; Cook-Scalise S; Pambudi I; Kadyrov A; Lawanson A; van den Hof S; Gebhard A; Juneja S; Sohn H
    BMJ Glob Health; 2022 Jan; 7(1):. PubMed ID: 34992077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe: author's response.
    Lange C; Kherabi Y; Guglielmetti L; Duarte R; Günther G;
    Clin Microbiol Infect; 2024 Sep; 30(9):1207-1208. PubMed ID: 38901496
    [No Abstract]   [Full Text] [Related]  

  • 15. A modified BPaL regimen for tuberculosis treatment replaces linezolid with inhaled spectinamides.
    Zohaib Ali M; Dutt TS; MacNeill A; Walz A; Pearce C; Lam H; Philp JS; Patterson J; Henao-Tamayo M; Lee R; Liu J; Robertson GT; Hickey AJ; Meibohm B; Gonzalez Juarrero M
    Elife; 2024 Oct; 13():. PubMed ID: 39378165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II-III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis.
    Berry C; du Cros P; Fielding K; Gajewski S; Kazounis E; McHugh TD; Merle C; Motta I; Moore DAJ; Nyang'wa BT
    Trials; 2022 Jun; 23(1):484. PubMed ID: 35698158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Availability of drugs for the treatment of multidrug-resistant/rifampicin-resistant tuberculosis in the World Health Organization European Region, October 2023.
    Otto-Knapp R; Edwards S; Kuchukhidze G; Kröger S; Häcker B; Bivol S; Yedilbayev A
    Euro Surveill; 2024 Apr; 29(17):. PubMed ID: 38666403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model.
    Li SY; Converse PJ; Betoudji F; Lee J; Mdluli K; Upton A; Fotouhi N; Nuermberger EL
    Antimicrob Agents Chemother; 2023 Apr; 67(4):e0003523. PubMed ID: 36920217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis.
    Ding Y; Zhu H; Fu L; Zhang W; Wang B; Guo S; Chen X; Wang N; Liu H; Lu Y
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0065822. PubMed ID: 35924925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis.
    Conradie F; Bagdasaryan TR; Borisov S; Howell P; Mikiashvili L; Ngubane N; Samoilova A; Skornykova S; Tudor E; Variava E; Yablonskiy P; Everitt D; Wills GH; Sun E; Olugbosi M; Egizi E; Li M; Holsta A; Timm J; Bateson A; Crook AM; Fabiane SM; Hunt R; McHugh TD; Tweed CD; Foraida S; Mendel CM; Spigelman M;
    N Engl J Med; 2022 Sep; 387(9):810-823. PubMed ID: 36053506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.